Systemic immunotoxin therapy of cancer: Advances and prospects

British Journal of Cancer

Volumn 64, Issue 4, 1991, Pages 624-630

  Wawrzynczak, E J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; MONOCLONAL ANTIBODY; RICIN A;

CANCER; HUMORAL IMMUNITY; IMMUNOGENICITY; PRIORITY JOURNAL; REVIEW; TARGET CELL; TOXICITY; TUMOR;

ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CLINICAL TRIALS; DRUG COMPOUNDING; IMMUNOTOXINS; NEOPLASMS; RICIN; SUPPORT, NON-U.S. GOV'T;

EID: 0025832346     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1991.374     Document Type: Review

References (64)

1. BAGSHAWE, K.D. (1989). Towards generating cytotoxic agents at cancer sites. Br. J. Cancer, 60, 275
2. BLAKEY, D C., SKILLETER, D.N., PRICE, R.J. & 4 others (1988a). Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A chain immunotoxins on murine liver parency- mal cells. Cancer Res., 48, 7072
3. BLAKEY, D C., WAWRZYNCZAK, E.J., WALLACE, P.M. & THORPE, P.E. (1988b). Antibody-toxin conjugates: a perspective. In Monoclonal Antibody Therapy, Waldmann, H. (ed.) Prog. Allergy, Vol. 45, p. 50, Karger: Basel
4. BLATTLER, W.A., LAMBERT, J.M. & GOLDMACHER, V.S. (1989). Realizing the full potential of immunotoxins. Cancer Cells, 1, 50
5. BOOKMAN, M.A., FITZGERALD, D., FRANKEL, A. & 12 others (1990a). Intraperitoneal immunotoxin therapy: two clinical studies. Antibody Immunoconj. Radiopharm., 3, 70
6. BOOKMAN, M.A., GODFREY, C., PADAVIC, H. & 5 others (1990b). Antitransferrin receptor immunotoxin therapy: phase I intraperitoneal trial. Proc. Annu. Meet. Am. Soc. Clin. Oncol., 9, 187
7. BYERS, V.S., RODVIEN, R., GRANT, H. & 4 others (1989). Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer. Cancer Res., 49, 6153
8. CHAUDHARY, V.K., GALLO, M.G., FITZGERALD, D.J. & PASTAN, I. (1990a). A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin. Proc. Natl Acad. Sci. USA, 87, 9491
9. CHAUDHARY, V.K., JINNO, Y., FITZGERALD, D. & Pastan I. (1990b). Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc. Natl Acad. Sci. USA, 87, 308
10. CHAUDHARY, V.K., JINNO, Y., GALLO, M.G., FITZGERALD, D. & PASTAN, I. (1990c). Mutagenesis of Pseudomonas exotoxin in identification of sequences responsible for animal toxicity. J. Biol. Chem., 265, 16306
11. CHAUDHARY, V.K., QUEEN, C., JUNGHANS, R.P., WALDMANN, T.A., FITZGERALD, D.J. & PASTAN, I. (1989). A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature, 339, 394
12. COLOMBATTI, M., Dell’arciprete, L., Chignola, R. & Tridente, G. (1990). Carrier protein-monensin conjugates: enhancement of immunotoxin cytotoxicity and potentiation in tumor treatment. Cancer Res., 50, 1385
13. CONDE, F.P., ORLANDI, R., CANEVARI, S. & 5 others (1989). The Aspergillus toxin restrictocin is a suitable cytotoxic agent for the generation of immunoconjugates with monoclonal antibodies directed against human carcinoma cells. Eur. J. Biochem., 178, 795
14. DURRANT, L.G., BYERS, V.S., SCANNON, P.J. & 5 others (1989). Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients. Clin. Exp. Immunol., 75, 258
15. EMBLETON, M.J. (1987). Drug-targeting by monoclonal antibodies. Br. J. Cancer, 55, 227
16. ENGERT, A., MARTIN, G., PFREUNDSCHUH, M. & 4 others (1990). Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin’s disease tumors in mice. Cancer Res., 50, 2929
17. EPENETOS, A.A. & KOSMAS, C. (1989). Monoclonal antibodies for imaging and therapy. Br. J. Cancer, 59, 152
18. FITZGERALD, D. & PASTAN, I. (1989). Targeted toxin therapy for the treatment of cancer. J. Natl Cancer Inst., 81, 1455
19. FRANKEL, A.E. (ed.) (1988). Immunotoxins, Kluwer: Boston
20. FULTON, R.J., TUCKER, T.F., VITETTA, E.S. & UHR, J.W. (1988a). Pharmacokinetics of tumor-reactive immunotoxins in tumorbearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization. Cancer Res., 48, 2618
21. 1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain. Cancer Res., 48, 2626
22. GHETIE, M.-A., MAY, R.D., TILL, M. & 10 others (1988). Evaluation of ricin A chain-containing immunotoxins directed against CD 19 and CD22 antigens on normal and malignant human B cells as potential reagents for in vivo therapy. Cancer Res., 48, 2610
23. 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins. Cancer Res., 51, 1482
24. GOULD, B.J., BOROWITZ, M.J., GROVES, E.S. & 4 others (1989). Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J. Natl Cancer Inst., 81, 775
25. HERTLER, A.A. & FRANKEL, A.E. (1989). Immunotoxins: a clinical review of their use in the treatment of malignancies. J. Clin. Oncol., 7, 1932
26. HERTLER, A.A., SCHLOSSMAN, DM., BOROWITZ, M.J., BLYTH-MAN, H.E., CASELLAS, P. & FRANKEL, A.E. (1989a). An anti-CD5 immunotoxin for chronic lymphyocytic leukemia: enhancement of cytotoxicity with human serum albumin- monensin. Int. J. Cancer, 43, 215
27. HERTLER, A.A., SCHLOSSMAN, D M., BOROWITZ, M.J., POPLACK, D.G. & FRANKEL, A.E. (1989b). An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Cancer Immunol. Immunother., 28, 59
28. 90Y-labelled Cl 10 anti- carcinoembryonic antigen immunotoxin: a therapeutic immuno- conjugate for human colon cancer. Cancer Res., 51, 255
29. JIN, F.-S., YOULE, R.J., JOHNSON, V.G. & 4 others (1991). Suppression of the immune response to immunotoxins with anti-CD4 monoclonal antibodies. J. Immunol., 146, 1806
30. JOHNSON, V.G., WILSON, D., GREENFIELD, L. & YOULE, R.J. (1988). The role of the diphtheria toxin receptor in cytosol translocation. J. Biol. Chem., 263, 1295
31. JOHNSON, V.G., WROBEL, C., WILSON, D. & 4 others (1989). Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J. Neurosurg., 70, 240
32. LAMBERT, J.M., MCINTYRE, G., GAUTHIER, M.N. & 5 Others (1991). The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry, 30, 3234
33. LOBUGLIO, A.F., KHAZAELI, M.B., LEE, J. & 4 others (1988). Pharmacokinetics and immune response to Xomazyme-Mel in melanoma patients. Antibody Immunoconj. Radiopharm., 1, 305
34. MANSKE, J.M., BUCHSBAUM, D.J., HANNA, D.E. & VALLERA, D A. (1988). Cytotoxic effects of anti-CD5 radioimmunotoxins on human tumors in vitro and in a nude mouse model. Cancer Res., 48, 7107
35. MAY, R.D., FINKELMAN, F.D., WHEELER, H.T., UHR, J.W. & VITETTA, E.S. (1990). Evaluation of ricin A chain-containing immunotoxins directed against different epitopes on the δ-chain of cell surface-associated IgD on murine B cells. J. Immunol., 144, 3637
36. MISCHAK, R.P., FOXALL, C., ROSENDORF, L.L., KNEBEL, K., SCAN-NON, P.J. & SPITLER, L.E. (1990). Human antibody responses to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin XomaZyme MEL. Mol. Biother., 2, 104
37. OGATA, M., CHAUDHARY, V.K., PASTAN, I. & FITZGERALD, D.J. (1990). Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37, 000 Da toxin fragment that is translocated to the cytosol. J. Biol. Chem., 265, 20678
38. O’hare, M., Brown, A.N., Hussain, K. & 6 others (1990). Cytotoxicity of a recombinant ricin A chain fusion protein containing a proteolytically-cleavable spacer sequence. FEBS Lett., 273, 200
39. ORATZ, R., SPEYER, J.L., WERNZ, J.C. & 4 others (1990). Antimelanoma monoclonal antibody-ricin A chain immunocon- jugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial. J. Biol. Resp. Modif., 9, 345
40. ORLANDI, R., CANEVARI, S., CONDE, F.P. & 4 others (1988). Immunoconjugate generation between the ribosome-inactivating protein restrictocin and an anti-human breast carcinoma MAB. Cancer Immunol. Immunother., 26, 114
41. PEARSON, J.W., FITZGERALD, D.J.P., WILLINGHAM, M.C., WIL-TROUT, R.H., PASTAN, I. & LONGO, D.L. (1989a). Chemo- immunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice. Cancer Res., 49, 3562
42. PEARSON, J.W., HEDRICH, E., FOGLER, W.E. & 8 others (1990). Enhanced therapeutic efficacy against ovarian tumor xenograft of immunotoxins used in conjunction with recombinant a-interferon. Cancer Res., 50, 6379
43. PEARSON, J.W., SIVAM, G., MANGER, R., WILTROUT, R.H., MORGAN, A.C. Jr & LONGO, D.L. (1989b). Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal tumour xenograft in athymic mice. Cancer Res., 49, 4990
44. PRESS, O.W., MARTIN, P.J., THORPE, P.E. & VITETTA, E.S. (1988). Ricin A chain-containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. J. Immunol., 141, 4410
45. RASO, V. & MCGRATH, J. (1989). Cure of experimental human malignant mesothelioma in athymic mice by diphtheria toxin. J. Natl Cancer Inst., 81, 623
46. Rostaing-Capaillon, O. & Casellas, P. (1990). Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo. Cancer Res., 50, 2909
47. SPITLER, L.E., MISCHAK, R. & SCANNON, P. (1989). Therapy of metastatic malignant melanoma using Xomazyme-Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin. Nucl. Med. Biol., 16, 625
48. STOUDEMIRE, J.B., MISCHAK, R., FOXALL, C., HARKONEN, W.S., DEL RIO, M. & SPITLER, L.E. (1990). The effects of cyclophosphamide on the toxicity and immunogenicity of ricin A chain immunotoxin in rats. Mol. Biother., 2, 179
49. SUNG, C., YOULE, R.J. & DEDRICK, R.L. (1990). Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability and binding. Cancer Res., 50, 7382
50. THORPE, P.E., WALLACE, P.M., KNOWLES, P.P. & 5 others (1988). Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A chain and hindered disulphide linkages. Cancer Res., 48, 6396
51. TILL, M., MAY, R.D., UHR, J.W., THORPE, P.E. & VITETTA, E.S. (1988). An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins. Cancer Res., 48, 1119
52. VITETTA, E.S., FULTON, R.J., MAY, R.D., TILL, M. & UHR, J.W. (1987). Redesigning nature’s poisons to create anti-tumor agents. Science, 238, 1098
53. VITETTA, E.S. & YEN, N. (1990). Expression and functional properties of genetically engineered ricin B chain lacking galactosebinding ability. Biochim. Biophys. Acta, 1049, 151
54. VON WUSSOW, P., SPITLER, L., BLOCH, B. & DEICHER, H. (1988). Immunotherapy in patients with advanced malignant melanoma using a monoclonal anti-melanoma antibody ricin A chain immunotoxin. Eur. J. Cancer Clin. Oncol., 24, Suppl. 2, S69
55. WAWRZYNCZAK, E.J., CUMBER, A.J., HENRY, R.V. & PARNELL, G.D. (1991a). Comparative biochemical, cytotoxic and pharmacokinetic properties of immunotoxins made with native ricin A chain, ricin A, chain and recombinant ricin A chain. Int. J. Cancer, 47, 130
56. WAWRZYNCZAK, E.J., CUMBER, A.J., PARNELL, G.D., DENHAM, S., JONES, P.T. & WINTER, G. (1991b). Pharmacokinetics of recombinant monoclonal antibodies with different biological properties. Br. J. Cancer, 63 (Suppl_XIII), 72
57. WAWRZYNCZAK, E.J., CUMBER, A.J., HENRY, R.V. & 5 others (1990). Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin and momordin. Cancer Res., 50, 7519
58. WAWRZYNCZAK, E.J. & DAVIES, A.J.S. (1990). Strategies in antibody therapy of cancer. Clin. Exp. Immunol., 82, 189
59. WAWRZYNCZAK, E.J., DRAKE, A.F., WATSON, G.J., THORPE, P.E. & VITETTA, E.S. (1988). Ricin B chain-containing immunotoxins prepared with heat-denatured B chain lacking galactose-binding ability potentiate the cytotoxicity of a cell-reactive ricin A chain immunotoxin. Biochim. Biophys. Acta, 971, 55
60. WAWRZYNCZAK, E.J., HENRY, R.V., CUMBER, A.J., PARNELL, G.D., DERBYSHIRE, E.J. & ULBRICH, N. (1991c). Biochemical, cytotoxic and pharmacokinetic properties of an immunotoxin composed of a mouse monoclonal antibody Fib75 and the ribosome-inactivating protein α-sarcin from Aspergillus giganteus. Eur. J. Biochem., 196, 203
61. WAWRZYNCZAK, E.J., WATSON, G.J., CUMBER, A.J. & 4 others (1991d). Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin. Cancer Immunol. Immunother., 32, 289
62. WEINER, L.M., O’dwyer, J., Kitson, J. & 5 others (1989). Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res., 49, 4062
63. WROBEL, C.J., WRIGHT, DC., DEDRICK, R.L. & YOULE, R.J. (1990). Diphtheria toxin effects on brain-tumor xenografts: implications for protein-based brain-tumor chemotherapy. J. Neurosurg., 72, 946
64. YOKOTA, S., HARA, H., LUO, Y. & SEON, B.K. (1990). Synergistic potentiation of in vivo antitumor activity of anti-human T- leukemia immunotoxins by recombinant a-interferon and daunorubicin. Cancer Res., 50, 32